Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie

Amcor Plc

Air Products and Chemicals

Franklin Resources

Cincinnati Financial

Chevron

Essex Property Trust

Federal Realty Investment Trust

Genuine Parts

Hormel Foods

NextEra Energy

Realty Income Corp

PepsiCo

T. Rowe Price Group

Walgreens

Exxon Mobil

"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years. "--Kiplinger.com/Investing. 66 Aristocrats, screened as of December 12, 2023, represented all eleven Morningstar Sectors. Broker estimated-top-ten net-gains ranged 13.71%-31.37% topped-by XOM & CVX. By yield, WBA topped-all Aristocrats. Top-ten Yields from ABBV, ESS, CVX, FRT, BEN, TROW, AMCR, O, MMM, & WBA, averaged 5.13%.

5 Dividend Aristocrats Signal Buy In December, With 6 To Watch

Medtronic PLC (NYSE:MDT) late Wednesday announced that the US Food and Drug Administration (FDA) has approved its PulseSelect Pulsed Field Ablation (PFA) system for the treatment of two heart conditions, paroxysmal and persistent atrial fibrillation, which can cause stroke or heart failure.     The medical technology company said its PFA is used for ablation procedures that treat atrial fibrillation using small burns or freezes to cause some scarring on the inside of the heart to help break up the electrical signals that cause irregular heartbeats.

Medtronic receives FDA approval for heart condition treatment; shares rise

Medtronic said the U.S. Food and Drug Administration has approved its PulseSelect Pulsed Field Ablation System for the treatment of two heart conditions.

Medtronic gets FDA approval for new heart-condition treatment

Medtronic said on Wednesday that the U.S. Food and Drug Administration (FDA) had approved its system for a type of condition that can cause stroke or heart failure.

US FDA approves Medtronic's system for heart condition

Safe, efficient, and effective treatment for both paroxysmal and persistent atrial fibrillation DUBLIN , Dec. 13, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the PulseSelect Pulsed Field Ablation (PFA) System for the treatment of both paroxysmal and persistent atrial fibrillation (AF). This is the first PFA technology to receive FDA approval and follows the recent European CE (Conformité Européenne) Mark of the PulseSelect PFA system in November.

Medtronic creates history with FDA approval of its novel PulseSelect™ Pulsed Field Ablation System to treat atrial fibrillation

Medtronic's (MDT) expanded collaboration with Cosmo Pharmaceuticals is a strategic step forward in its quest to use AI to improve patient care.

Medtronic (MDT) Expands AI-Driven Care With New Partnership

Significant Upside Potential: Both models project strong growth for Medtronic, with the first indicating a remarkable 130.3% increase and the more conservative second model predicting a compelling 26.7% annual return. Diverse Analytical Approaches: The analysis encompasses various methodologies, including analysts' estimates, market-based segmentation, and a conservative revenue prediction model, enhancing the overall depth and reliability of the assessment. Resilient Financial Performance: Medtronic's proactive cost-cutting strategy, aiming for $1 billion in savings by 2025, reflects financial resilience and positions the company for future growth amid healthcare challenges.

Medtronic: An Undervalued Gem In The Medical Devices Sector (Ratings Upgrade)

Albemarle

Amazon

Alibaba

Bilibili

Bristol-Myers

Farfetch

JD.com

KeyCorp

Lucid Group

ModivCare

Nikola

NetEase

Organon & Co

Pinduoduo Inc - ADR

Pfizer

Insulet

PayPal

Sibanye Stillwater

Charles Schwab

Seagen

Block

Tencent Holdings Limited

Tandem Diabetes Care

VinFast Auto Ltd

Investors should consider tax-loss selling before December ends to offset capital gains. Two characteristics to consider for selling stocks are stocks bought at a higher price and broken companies with weak long-term prospects. Stock grades, sentiment, and fundamentals assessed.

8 Tax-Loss Sell Alerts For December

Agreement Expands Partnership Between Cosmo Pharmaceuticals and Medtronic, Set to Transform Endoscopy with Cutting-Edge AI Technology Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - December 11, 2023) - Cosmo Pharmaceuticals (SIX: COPN) (XETRA: C43) (“Cosmo”) announces that its subsidiary Cosmo Intelligent Medical Devices has entered into a definitive agreement to expand its partnership with Medtronic plc (NYSE: MDT), a global leader in healthcare technology.

Cosmo Pharmaceuticals and Medtronic Forge Ahead in AI-Driven Care

Agreement expands partnership between Medtronic and Cosmo Pharmaceuticals, set to transform endoscopy with cutting-edge AI technology DUBLIN , Dec. 11, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announces that it has entered into a definitive agreement to expand its partnership with Cosmo Intelligent Medical Devices, a subsidiary of Cosmo Pharmaceuticals. This AI-driven partnership will further capitalize on the achievements already realized with the GI Genius™ intelligent endoscopy module, offering continued innovation and scalable healthcare advancements for patients and caregivers globally.

Medtronic and Cosmo Pharmaceuticals forge ahead in AI-driven care

Mr. Market has overemphasized the potential negative impacts of GLP-1 drugs on conventional diabetes care since there is no miracle one-time drug. Medtronic's bottom lines have also been impacted by the elevated inflationary pressure and FX headwinds, naturally depressing its profitability metrics compared to pre-pandemic levels. However, we are not overly concerned since the diabetes segment only accounts for a small portion of its sales, with the PPI inflation already cooling.

Medtronic: The GLP-1 Drug Headwinds Are Overblown

DUBLIN , Dec. 7, 2023 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, December 7, 2023, approved the company's cash dividend for the third quarter of fiscal year 2024 of $0.69 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2023.

Medtronic announces cash dividend for third quarter of fiscal year 2024

Charles River Laboratories

Johnson & Johnson

In 2016, there were 49 million Americans aged 65 or older. Analysts forecast that will grow to 73 million retirement-age Americans in 2030 and an eye-opening 95 million in the year 2060.

Investing in the Aging Population: 3 Healthcare Stocks to Watch

Raytheon Technologies

AT&T

It's understandable if you have whiplash from market moves this year. We've seen stocks surge, fall and surge again on the heels of the current Santa rally.

Solid as a Rock: 3 Blue-Chip Stocks for a Stable Portfolio

Southwest Airlines

Medical device maker Medtronic should benefit from a return to normality in the healthcare industry. United Parcel Service ought to experience better growth as macroeconomic conditions improve.

Got $5,000? These 3 Stocks Are Deep-Value Buys Right Now

These companies all have solid histories of dividend increases and are making future dividend payments a priority. You can likely count on them to grow your passive income from year to year.

Looking for Dividend Growth in the New Year? 3 Magnificent Stocks to Buy Now.

Alphabet

The market's recovery could continue into 2024 -- and these stocks should benefit. Medtronic boasts a steady business and an incredible dividend track record.

A Bull Market Is Coming: 2 Top Stocks to Buy Hand Over Fist

Medtronic's recent earnings report has boosted investor confidence, suggesting the worst may be over for the company. The impact of the weight loss drugs on Medtronic's long-term growth prospects is expected to be limited and could be overstated. MDT's valuation isn't cheap relative to its sector peers, but its best-in-class profitability grade likely justifies the premium.

Medtronic: On The Verge Of A Massive Turnaround

Medtronic has revamped its business to favor growth. There are other stocks out there offering higher growth rates and longer streaks of payout hikes.

Medtronic Stock: Bull vs. Bear

Palantir Technologies

AST SpaceMobile

The top tech stocks are always a point of contention among investors. Some prefer sticking with reliable companies like the Magnificent 7, while others decry the same for being grossly overvalued.

If You Can Only Buy One Tech Stock in December, It Better Be One of These 3 Names

Medtronic is a well-diversified healthcare company with strong secular growth and pricing power. The company has four major business segments, each contributing over $2 billion in annual revenue. Medtronic's recent financial results have exceeded expectations, and the company has adjusted its full-year guidance upward.

3.5% Yield And Over 15% Annual Return Potential - I Really Like Medtronic

Brown & Brown

In my monthly series of 10 Dividend Growth Stocks, I rank a selection of Dividend Radar stocks and present the 10 top-ranked stocks for further research and possible investment. This month, I'm presenting high-quality stocks with the highest defensiveness scores based on a scoring system developed by David Van Knapp. I ranked candidates by considering, in turn, their Dividend Safety Scores and their Beta measure of volatility.

10 Dividend Growth Stocks For November 2023

News for Medtronic Stock (MDT)